Literature DB >> 34143682

Dietary Consumption Among Youth with Antipsychotic-Induced Weight Gain and Changes Following Healthy Lifestyle Education.

Kristin Bussell1,2, Gloria Reeves2, Erin Hager3, Shijun Zhu4, Christoph U Correll5,6,7, Mark A Riddle8, Linmarie Sikich9.   

Abstract

Background: Youth treated with antipsychotic medications are high risk for weight gain, increased lipids/glucose, and development of metabolic syndrome. Little is known about the dietary intake/nutritional adequacy in this vulnerable population, and effect on weight gain. This secondary data analysis describes the baseline intake and changes in diet after receiving healthy lifestyle education/counseling over 6 months, in a sample of youth with antipsychotic-induced weight gain.
Methods: The U.S. Department of Agriculture (USDA) Automated Multiple-Pass Method 24-hour dietary recall was administered to 117 youth at baseline, 3 months, and 6 months. Parent/child received personalized healthy lifestyle education sessions over 6 months. Baseline intake was compared with the USDA Recommended Daily Allowance using independent samples t-tests. Individual dietary covariates were examined for change over 6 months using longitudinal linear mixed modeling. Influence of each on body mass index (BMI) z-score change was tested in a pooled group analysis and then compared by treatment group.
Results: Pooled analysis revealed baseline consumption high in carbohydrates, fat, protein, sugar, and refined grains, while low in fruit/vegetables, whole grains, fiber, and water. Change over 6 months demonstrated a statistically significant decrease in daily calories (p = 0.002), carbohydrates (p = 0.003), fat (p = 0.012), protein (p = 0.025), sugar (p = 0.008), refined grains (p = 0.008), total dairy (p = 0.049), and cheese (p = 0.027). Small increases in fruits/vegetables were not statistically significant, although the Healthy Eating Index subscores for total vegetables (p = 0.013) and dark green/orange vegetables (p = 0.034) were. No dietary covariates were predictors of change in BMI z-score. Nondietary predictors were parent weight/BMI and treatment group, with the metformin and switch groups experiencing significant decreases in BMI z-score. Conclusions: Further pediatric studies are necessary to assess the effects of antipsychotic medications on dietary intake, and test efficacy of healthy lifestyle interventions on change in nutrition. The relationship of nutrition to cardiometabolic health in this population must be further investigated. Clinical Trial Registration number: NCT02877823.

Entities:  

Keywords:  dietary intake/nutrition; pediatric antipsychotic treatment; weight loss

Mesh:

Substances:

Year:  2021        PMID: 34143682      PMCID: PMC8233214          DOI: 10.1089/cap.2020.0173

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   3.031


  44 in total

1.  Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.

Authors:  David M Rubin; Amanda R Kreider; Meredith Matone; Yuan-Shung Huang; Chris Feudtner; Michelle E Ross; A Russell Localio
Journal:  JAMA Pediatr       Date:  2015-04-06       Impact factor: 16.193

2.  Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial.

Authors:  Christoph U Correll; Linmarie Sikich; Gloria Reeves; Jacqueline Johnson; Courtney Keeton; Marina Spanos; Sandeep Kapoor; Kristin Bussell; Leslie Miller; Tara Chandrasekhar; Eva M Sheridan; Sara Pirmohamed; Shauna P Reinblatt; Cheryl Alderman; Abigail Scheer; Irmgard Borner; Terrence C Bethea; Sarah Edwards; Robert M Hamer; Mark A Riddle
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

3.  Dietary sources of energy, solid fats, and added sugars among children and adolescents in the United States.

Authors:  Jill Reedy; Susan M Krebs-Smith
Journal:  J Am Diet Assoc       Date:  2010-10

4.  Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

Authors:  Randall Owen; Linmarie Sikich; Ronald N Marcus; Patricia Corey-Lisle; George Manos; Robert D McQuade; William H Carson; Robert L Findling
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

5.  The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes.

Authors:  Alanna J Moshfegh; Donna G Rhodes; David J Baer; Theophile Murayi; John C Clemens; William V Rumpler; David R Paul; Rhonda S Sebastian; Kevin J Kuczynski; Linda A Ingwersen; Robert C Staples; Linda E Cleveland
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

6.  Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.

Authors:  Christoph U Correll; Lawrence Maayan; John Kane; Marc De Hert; Dan Cohen
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384

7.  Childhood obesity: highlights of AMA Expert Committee recommendations.

Authors:  Goutham Rao
Journal:  Am Fam Physician       Date:  2008-07-01       Impact factor: 3.292

Review 8.  Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.

Authors:  Noor B Almandil; Ying Liu; Macey L Murray; Frank M C Besag; Katherine J Aitchison; Ian C K Wong
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Trends in mental health care among children and adolescents.

Authors:  Mark Olfson; Benjamin G Druss; Steven C Marcus
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

10.  Dietary fibre and whole grains in diabetes management: Systematic review and meta-analyses.

Authors:  Andrew N Reynolds; Ashley P Akerman; Jim Mann
Journal:  PLoS Med       Date:  2020-03-06       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.